Luitpold Pharmaceuticals and American Regent Agreed to Pay $1.2 Million for Allegedly Violating the Civil Monetary Penalties Law by Paying Remuneration to a Physician and Practice in the Form of Payments Made for an Anemia Management Pilot Program
On July 21, 2017, Luitpold Pharmaceuticals, Inc. (LPI) and American Regent, Inc. (ARI), entered into a $1,237,100 settlement agreement with OIG. Daiichi Sankyo, Inc. made a disclosure submission concerning its subsidiaries LPI and ARI pursuant to its CIA. (LPI and ARI are "Daiichi Affiliates" covered by certain CIA requirements.) The settlement agreement resolves allegations that LPI and ARI provided remuneration to a physician and her practice in the form of payments made and services provided in connection with an iron deficiency anemia management pilot program.
- Date:July 21, 2017
- CIA Reportable Events